In brief
- MAPS responded on 10 August to reporting about a Resilient resubmission to FDA; a regulatory receipt or acceptance was not reviewed here.
- MAPS describes a resubmission without a new phase 3 trial; its release does not document here a 32-person phase 1 study, audits or third-party records.
- The announcement does not establish approval or guarantee FDA acceptance, a review timetable or a favorable decision.
Two years after the U.S. Food and Drug Administration (FDA) stalled the first application for approval of MDMA-assisted therapy for post-traumatic stress disorder (PTSD), the company behind the treatment is trying again. Resilient Pharmaceuticals, the successor to the clinical program that was driven for decades by the nonprofit MAPS (Multidisciplinary Association for Psychedelic Studies), is the company to which Psychedelic Alpha reporting on 9 August attributed an NDA resubmission. MAPS responded the next day and states that it has no active role in the current development programme. This review read MAPS’s release, not the dossier or an FDA receipt.
What the FDA requested and what has changed
In MAPS’s account, the August 2024 complete response letter (CRL) recommended additional research on three fronts: a more robust characterization of treatment safety, data on the durability of the effect over time, and measures to reduce the risk of bias stemming from the fact that participants and therapists could often guess who had received MDMA and who had received a placebo, given how difficult it is to mask the substance’s subjective effects. MAPS describes a resubmission without a new phase 3 trial. The inspected release does not detail a 32-person phase 1 study, an independent audit or third-party Veterans Affairs records; those claims are not presented as verified dossier documents. Without the dossier, this review cannot assess whether every recommendation has been addressed.
A three-decade program
The dossier is supported by research that MAPS funded from the early 1990s until 2022—two phase 3 trials and five phase 2 trials already published—and MAPS reports more than $150 million donated since 1986 for research, policy and culture; this is not a budget exclusive to that dossier. Rick Doblin, founder of MAPS, noted that “we knew the FDA wasn’t saying no, but rather not yet,” while Betty Aldworth, the organization’s co-executive director, emphasized that the clarity of the agency’s instructions “was earned by the researchers, therapists, and participants who believe this treatment deserves a rigorous evaluation.” MAPS also cites final FDA guidance from July 2026 on psychedelic clinical investigations. This review did not inspect that regulatory document or infer dossier acceptance from its existence.
What this implies
The release is the position of an organization linked to the historical programme, not a regulatory decision. Data validity, safety and bias control require documentation and evaluation; its representatives’ statements remain attributed opinions. A reported resubmission and general guidance do not guarantee approval or routine access. A regulatory application’s outcome is distinct from harm reduction that any person can practice today, inside or outside of a trial.
Related previous coverage: Blinding fails in more than 85% of MDMA and placebo trials.
Source
- MAPS. MAPS Responds to Report of Progress for MDMA-assisted therapy for PTSD with FDA. Multidisciplinary Association for Psychedelic Studies, August 10, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
